{"id":"riboflavin-uv-rbc","safety":{"commonSideEffects":[{"rate":null,"effect":"Hemolysis or reduced RBC viability"},{"rate":null,"effect":"Transfusion reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This is a pathogen reduction technology (PRT) for blood products. Riboflavin (vitamin B2) acts as a photosensitizer that, when activated by UV-A or UV-B light, generates reactive oxygen species that damage nucleic acids in pathogens (bacteria, viruses, parasites) and inactivate them while minimizing damage to RBC viability and function. The treated blood product retains adequate hemoglobin function for transfusion while reducing infectious disease transmission risk.","oneSentence":"Riboflavin combined with ultraviolet (UV) light exposure inactivates pathogens in red blood cells to reduce transfusion-transmitted infections.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:32:08.215Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reduction of transfusion-transmitted infections in red blood cell products"},{"name":"Pediatric hematologic disorders requiring transfusion support"}]},"trialDetails":[{"nctId":"NCT03426553","phase":"PHASE3","title":"Clinical Use of Pathogen Reduced Red Blood Cell Suspension","status":"COMPLETED","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2018-01-15","conditions":"Oncologic Disorders, Hematologic Diseases","enrollment":50},{"nctId":"NCT01907906","phase":"PHASE1","title":"Inactivation of Whole Blood With Mirasol","status":"COMPLETED","sponsor":"Terumo BCTbio","startDate":"2013-06","conditions":"Focus of Study: Radiolabel Recovery and Survival of RBCs","enrollment":29}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Riboflavin+UV RBC","genericName":"Riboflavin+UV RBC","companyName":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","companyId":"federal-research-institute-of-pediatric-hematology-oncology-and-immunology","modality":"Biologic","firstApprovalDate":"","aiSummary":"Riboflavin combined with ultraviolet (UV) light exposure inactivates pathogens in red blood cells to reduce transfusion-transmitted infections. Used for Reduction of transfusion-transmitted infections in red blood cell products, Pediatric hematologic disorders requiring transfusion support.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}